The Biden administration could exacerbate the drug crisis by strong-arming state authorities to up distribution of prescription opioids. As a former drug court judge and a person in long term recovery, I think that’s a bad idea.

The Justice Department is suing Pennsylvania drug courts under federal civil rights law for requiring that some people with opioid use disorder (OUD) ween off of medication-assisted treatment (MAT) drugs. The department argues that MATs are a civil right for drug court defendants.

Euphoria and addiction

The two most common forms of MAT are methadone and buprenorphine. Both are synthetic opioids that produce euphoria. These drugs do not cure OUD. They alleviate adverse symptomology and allow people to move forward with their lives.

Advertise with us

The manufacturers of these drugs know they can be abused. Reckitt Benckiser and their spinoff Indivior have paid out hundreds of millions for making dishonest claims that their MAT products were safe from misuse.

Unfortunately, the Biden administration is amplifying this industry falsehood. The government’s entire lawsuit is predicated upon the false premise that methadone and buprenorphine do not produce euphoria. The Justice Department claimed as much in a letter to state authorities in February 2022.

Because MAT can be abused, because each defendant is different, courts and prison officials must have discretion to impose conditions on treatment. There are legitimate reasons to require that a defendant curtail their use of MAT. Thanks to DOJ’s lawsuit, drug court judges or medical practitioners will avoid intervening with a person abusing their MAT prescriptions for fear of a civil rights violation.

The authorities in Pennsylvania have learned this by experience as well. The Department of Corrections began processing inmate mail at an offsite facility after intercepting parcels soaked in drugs in 2018. Among the drugs they intercepted, according to press accounts, were synthetic cannabinoids, fentanyl, and suboxone, which is brand name buprenorphine.

Indefinite treatment

Advertise with us

The Justice Department’s 2022 letter and subsequent lawsuit maintain that some MAT treatments can be “indefinite.” DOJ’s lawsuit states that MAT yields a 50 percent reduction in overdoses. But this positive outcome assumes patients have therapeutic support and ongoing clinical oversight. Therefore, an indefinite prescription should be predicated on each patient’s unique needs to help them live the miracle of recovery.

The Justice Department’s own lawsuit undermines the case for perpetual MAT treatment. Because buprenorphine is an opioid, detoxing sometimes involves inpatient rehabilitation care consistent with other addictive narcotics. Individuals cited in its complaint reported withdrawal symptoms when courts ordered them to stop taking buprenorphine.

One individual, for example, was prescribed buprenorphine to treat methamphetamine and heroin addiction. When a Pennsylvania court required him to ween off of buprenorphine, he entered inpatient care where “he had no appetite, he routinely vomited, his body twitched, and he felt like he wanted to die.”

Having been a drug court judge and being someone in recovery, I believe that a person using MAT as directed is indeed in recovery and living a miracle. But my drug court integrated MAT along with the federal government’s Ten Key Components of Drug Court, peer support, life skills training, and therapy. The Justice Department’s approach negates these best practices and gives no credence to individual characteristics and needs.

Patient-centric practice

Advertise with us

Pennsylvania should defend its wise and patient-centric practices against the Biden administration’s one-size-fits-all policy. Otherwise, patient-centric providers at the front lines of the opioid crisis face the unwelcome prospect of a federal civil rights investigation.

Last week a court client emailed me to celebrate twelve years of sobriety, and shared all the ways their life has changed for the better. This is the miracle we can attain when we tailor treatment to the unique attributes of each patient, instead of strong-arming drug courts to hand out more opioids.

Katharine Sullivan, a former senior advisor to the White House Domestic Policy Council and trial court judge in Colorado, sits on the board of Recovery for America Now Foundation. The Ten Key Components of Drug Court can be found here.